181 related articles for article (PubMed ID: 32222727)
1. Baseline quality of life predicts overall survival in patients with mCRPC treated with
Frantellizzi V; De Feo MS; Di Rocco A; Pontico M; Pani A; Farcomeni A; Cosma L; Lazri J; De Vincentis G
Hell J Nucl Med; 2020; 23(1):12-20. PubMed ID: 32222727
[TBL] [Abstract][Full Text] [Related]
2.
Dizdarevic S; Jessop M; Begley P; Main S; Robinson A
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2264-2273. PubMed ID: 29998419
[TBL] [Abstract][Full Text] [Related]
3. Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study.
Frantellizzi V; Monari F; Mascia M; Costa R; Rubini G; Spanu A; Farcomeni A; Lodi Rizzini E; Cindolo L; Licari M; Lavelli V; Nuvoli S; Ricci M; Dionisi V; Nappi AG; De Vincentis G
Int J Radiat Biol; 2020 Dec; 96(12):1608-1613. PubMed ID: 33074066
[TBL] [Abstract][Full Text] [Related]
4. A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with
Frantellizzi V; Farcomeni A; Follacchio GA; Pacilio M; Pellegrini R; Pani R; De Vincentis G
Ann Nucl Med; 2018 Feb; 32(2):142-148. PubMed ID: 29285670
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy.
van der Doelen MJ; Oving IM; Wyndaele DNJ; van Basten JP; Terheggen F; van de Luijtgaarden ACM; Oyen WJG; van Schelven WD; van den Berkmortel F; Mehra N; Janssen MJR; Prins JB; Gerritsen WR; Custers JAE; van Oort IM
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):142-150. PubMed ID: 35804188
[TBL] [Abstract][Full Text] [Related]
6. Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy.
Sraieb M; Hirmas N; Conrad R; Marinova M; Essler M; Herrmann K; Ahmadzadehfar H
Medicine (Baltimore); 2020 Sep; 99(38):e22287. PubMed ID: 32957385
[TBL] [Abstract][Full Text] [Related]
7. Validation of the 3-variable prognostic score (3-PS) in mCRPC patients treated with
Frantellizzi V; Monari F; Mascia M; Costa R; Rubini G; Spanu A; Di Rocco A; Lodi Rizzini E; Cindolo L; Licari M; Lavelli V; Nuvoli S; De Angelis C; Dionisi V; Ferrari C; De Vincentis G
Ann Nucl Med; 2020 Oct; 34(10):772-780. PubMed ID: 32654030
[TBL] [Abstract][Full Text] [Related]
8. Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients.
Fosbøl MØ; Petersen PM; Daugaard G; Holm S; Kjaer A; Mortensen J
Ann Nucl Med; 2018 Jan; 32(1):16-21. PubMed ID: 28975586
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen flare induced by
Castello A; Macapinlac HA; Lopci E; Santos EB
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
[TBL] [Abstract][Full Text] [Related]
10. Impact of pre-treatment variables on the completion of
Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
[TBL] [Abstract][Full Text] [Related]
11. Assessing Radiographic Response to
Anand A; Trägårdh E; Edenbrandt L; Beckman L; Svensson JH; Thellenberg C; Widmark A; Kindblom J; Ullén A; Bjartell A
J Nucl Med; 2020 May; 61(5):671-675. PubMed ID: 31586004
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic Value of Quantitative Bone SPECT/CT Before
Dittmann H; Kaltenbach S; Weissinger M; Fiz F; Martus P; Pritzkow M; Kupferschlaeger J; la Fougère C
J Nucl Med; 2021 Jan; 62(1):48-54. PubMed ID: 32444369
[TBL] [Abstract][Full Text] [Related]
13. Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.
Yamamoto Y; Okuda Y; Kanaki T; Tanaka R; Nagahara A; Nakai Y; Nakayama M; Kakimoto KI; Nishimura K
Int J Clin Oncol; 2021 Jan; 26(1):192-198. PubMed ID: 32875513
[TBL] [Abstract][Full Text] [Related]
14. Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment.
Frantellizzi V; Pani A; Ippoliti MD; Farcomeni A; Aloise I; Colosi M; Polito C; Pani R; Vincentis G
Radiol Oncol; 2019 Dec; 54(1):40-47. PubMed ID: 31855572
[TBL] [Abstract][Full Text] [Related]
15. Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer -5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life.
Jiang XY; Atkinson S; Pearson R; Leaning D; Cumming S; Burns A; Azzabi A; Frew J; McMenemin R; Pedley ID
Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e177-e187. PubMed ID: 32448724
[TBL] [Abstract][Full Text] [Related]
16. Baseline
García Vicente AM; González García B; Amo-Salas M; García Carbonero I; Cassinello Espinosa J; Gómez-Aldaraví Gutierrez JL; Suarez Hinojosa L; Soriano Castrejón Á
Clin Transl Oncol; 2019 Mar; 21(3):289-297. PubMed ID: 30006674
[TBL] [Abstract][Full Text] [Related]
17. A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer.
Miyoshi Y; Tsutsumi S; Yasui M; Kawahara T; Uemura KI; Hayashi N; Nozawa M; Yoshimura K; Uemura H; Uemura H
World J Urol; 2021 Sep; 39(9):3323-3328. PubMed ID: 33644830
[TBL] [Abstract][Full Text] [Related]
18. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract][Full Text] [Related]
19. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.
Nilsson S; Cislo P; Sartor O; Vogelzang NJ; Coleman RE; O'Sullivan JM; Reuning-Scherer J; Shan M; Zhan L; Parker C
Ann Oncol; 2016 May; 27(5):868-74. PubMed ID: 26912557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
